Cardiac mapping platform receives FDA clearance
Click Here to Manage Email Alerts
Abbott announced its cardiac mapping platform for electrophysiology procedures received clearance from the FDA.
The platform (Ensite X EP System with Ensite Omnipolar Technology) creates detailed 3D maps of the heart to help operators identify and treat areas where arrhythmias originate, according to a press release from the company.
“More patients than ever before are benefiting from ablation to treat abnormal heart rhythms, and Abbott’s new EnSite X System with EnSite OT, utilizing Advisor HD Grid catheter,embodies the latest innovation available to support the treatment of complex and challenging cardiac arrhythmias,” Amin Al-Ahmad, MD, a clinical cardiac electrophysiologist with Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas, said in the release. “To continue improving outcomes for our patients, we need a system with speed, stability and accuracy. Abbott has provided us with a system that not only supports safe and effective treatment, but enhances the accuracy of maps, allowing for a clearer understanding of what is going on in the heart and what areas need to be targeted with ablation to treat arrythmias.”
The system can map more than 1 million points in the heart, which enables more precise location of areas to treat, the company stated in the release.
Collapse
Read more about
Click Here to Manage Email Alerts